Syndax Pharmaceuticals (SNDX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.55

Estimate

-$0.48

Surprise

-13.7%

Revenue (period 2026-09-30)

$83.3M

Score today

5.9/10

Revenue source: xbrl.

Syndax Pharmaceuticals (SNDX) reported a wider loss than forecast — adjusted EPS of -$0.55 against the -$0.48 estimate (a 13.7% shortfall).

• HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36 — benzinga, 2026-11-03
• Syndax Pharmaceuticals Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-02
• Syndax Pharmaceuticals Appoints Aaron A. Ondrey as Chief Financial Officer — fiscal.ai, 2026-11-02

TrendMatrix currently rates SNDX Sell at 5.9/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -13.7% surprise compares with a -14.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$13.10

Price target

$32.43

Stop

$12.41

Upside to target

+147.6%

Reward-to-risk

15.0:1

Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.16B

P/E (fwd)

-17.9

52-week range

$12.79–$25.59

Off 52-week high

48.8%

RSI (14)

41

Volume vs avg

1.11×

Score today

5.9/10